Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pol Specenier

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Oncologist|December 30, 2015
Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-AnalysisOlivier M Vanderveken, Petr Szturz, Pol Specenier, et al.
Cancers|December 5, 2019
Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 StatusJolien Van den Bossche, Andreas Domen, Marc Peeters, et al.
Cancer Letters|September 7, 2014
Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteinsCarolien Boeckx, Ken Op de Beeck, An Wouters, et al.
Molecular Oncology|March 13, 2019
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53Jolien Van den Bossche, Christophe Deben, Ines De Pauw, et al.
Cancer|August 16, 2016
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Jean-Pascal Machiels, Lori Wirth, et al.
Trials|September 6, 2015
Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?Gwen Van Nuffelen, Leen Van den Steen, Olivier Vanderveken, et al.
BMC Research Notes|June 6, 2014
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseCarolien Boeckx, Christine Weyn, Isabelle Vanden Bempt, et al.
The Oncologist|February 13, 2015
Helical tomotherapy in head and neck cancer: a European single-center experienceDirk Van Gestel, Danielle Van den Weyngaert, Geert De Kerf, et al.
Plos One|June 11, 2021
Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapyMargot Geens, Sofie Stappers, Heleen Konings, et al.
Journal of Neurology|January 10, 2015
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastomaJohnny Duerinck, Paul M Clement, Frank Bouttens, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Oncologist|December 30, 2015
Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-AnalysisOlivier M Vanderveken, Petr Szturz, Pol Specenier, et al.
Cancers|December 5, 2019
Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 StatusJolien Van den Bossche, Andreas Domen, Marc Peeters, et al.
Cancer Letters|September 7, 2014
Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteinsCarolien Boeckx, Ken Op de Beeck, An Wouters, et al.
Molecular Oncology|March 13, 2019
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53Jolien Van den Bossche, Christophe Deben, Ines De Pauw, et al.
Cancer|August 16, 2016
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Jean-Pascal Machiels, Lori Wirth, et al.
Trials|September 6, 2015
Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?Gwen Van Nuffelen, Leen Van den Steen, Olivier Vanderveken, et al.
BMC Research Notes|June 6, 2014
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment responseCarolien Boeckx, Christine Weyn, Isabelle Vanden Bempt, et al.
The Oncologist|February 13, 2015
Helical tomotherapy in head and neck cancer: a European single-center experienceDirk Van Gestel, Danielle Van den Weyngaert, Geert De Kerf, et al.
Plos One|June 11, 2021
Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapyMargot Geens, Sofie Stappers, Heleen Konings, et al.
Journal of Neurology|January 10, 2015
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastomaJohnny Duerinck, Paul M Clement, Frank Bouttens, et al.
Pageof 6